SCHEMBL30984066

SCHEMBL30984066

CC1(Oc2nccc(NCc3cc(Cl)ccn3)c2[N+](=O)[O-])CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 9/20 0.38
▸ IGF1R P08069 9/20 0.38
▸ PKM P14618 2/20 0.34
▸ MAPT P10636 3/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ ARNT P27540 1/20 0.32
▸ EPAS1 Q99814 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ BACE1 P56817 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ WDR5 P61964 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30984008 0.86 EGFR (0.39) EGFRIGF1RPKMMAPTALDH1A1
SCHEMBL30983969 0.82 ALDH1A1 (0.34) EGFRIGF1RPKMMAPTALDH1A1
SCHEMBL30983977 0.82 KCNH2 (0.35) EGFRIGF1RPKMBACE1WDR5
SCHEMBL30984084 0.72 CA1 (0.44) EGFRL3MBTL1ALDH1A1KMT2ANPC1
SCHEMBL31269026 0.72 CA1 (0.46) EGFRIGF1RMAPTALDH1A1SMN1; SMN2
SCHEMBL30983904 0.70 KCNH2 (0.38) ALDH1A1SMN1; SMN2BACE1WDR5
SCHEMBL30983870 0.68 MEN1 (0.32) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL30983787 0.67 MEN1 (0.31) ALDH1A1MEN1KMT2A
SCHEMBL31269514 0.67 CA1 (0.44) EGFRMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL30983974 0.66 KMT2A (0.31) MAPTALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback